AMESITE INC

Company Overview

Amesite Inc. is a small, Michigan‑based software company that in FY2025 pivoted from higher‑education products to healthcare under the NurseMagic™ brand, offering AI‑powered workflow, documentation, compliance and HIPAA‑compliant communication tools for post‑acute care providers. NurseMagic is sold both as a B2C mobile app (free + paid subscriptions) to individual nurses/caregivers and as a B2B enterprise platform for home health, skilled nursing, hospice and senior living operators; the company emphasizes rapid feature cadence, modular architecture and a mix of proprietary AI models and third‑party tech. The business is capital‑light and lean (6 full‑time employees + consultants), backed by a small patent portfolio (14 U.S. patents) and recurring subscription pricing, but faces material regulatory and procurement risks (HIPAA/HITECH, CMS, FTC/HHS oversight), strong competition from EHR/EMR vendors and a constrained cash runway that has required recent equity financings.

Executive Compensation Practices

As a Technology / Software‑Application company undergoing a strategic pivot, Amesite is likely to rely disproportionately on equity‑linked compensation (options, RSUs, warrants) and milestone‑linked awards rather than large cash salaries—consistent with its small headcount, recent reductions in cash operating costs, and explicit use of stock‑based compensation in filings. Company performance drivers that would reasonably determine pay are customer adoption metrics (B2C conversion and retention), recurring revenue/ARR growth from enterprise NurseMagic deployments, successful HIPAA/compliance certifications or enterprise feature launches, and IP milestones (patent filings/awards). The 10‑K/10‑Q also highlight capitalization and amortization of internal software (ASC 350‑40) and Black‑Scholes assumptions for option valuation, so accounting judgments on capitalization, impairment and valuation materially affect reported compensation expense and could influence award sizing/timing. Management’s recent reductions in stock‑based comp and headcount to conserve cash suggest near‑term emphasis on preserving liquidity, so future grants may be used strategically for retention and to incentivize successful financings or enterprise contract wins.

Insider Trading Considerations

Given Amesite’s small float, low liquidity and recurring reliance on equity financings (notably the Jan 8, 2025 offering), insider transactions can have outsized market impact and often signal liquidity needs versus confidence in the pivot—watch Form 4 filings closely around announced financings and post‑offering periods. Material nonpublic events for this company likely include major enterprise customer signings, HIPAA/compliance or enterprise‑security certifications, feature or product milestones (e.g., Enterprise offering launches), Nasdaq listing compliance notices, and financing negotiations; such items could be material under securities laws and should precede any trading blackout windows. Also monitor option exercises, warrant conversions and insider sales following equity raises (common in early‑stage software firms), and look for disclosure of 10b5‑1 plans or grant timing; in this healthcare software context, operational confidentiality (customer data, compliance issues) increases the sensitivity of potential material information even though HIPAA itself does not govern insider trading.